Gilead to acquire Immunomedics for $21 billion

Gilead Sciences will acquire biopharmaceutical company Immunomedics for $21 billion, the company announced on Sunday. The acquisition will expand Gilead's portfolio of treatments for various types of cancer.

Gilead to acquire Immunomedics for $21 billion
Gilead Sciences will acquire biopharmaceutical company Immunomedics for $21 billion, the company announced on Sunday. The acquisition will expand Gilead's portfolio of treatments for various types of cancer.